Cargando…

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

BACKGROUND: Guanfacine is a α2A adrenergic receptor agonist approved for treating attention deficit hyperactivity disorder (ADHD). It is thought to act via postsynaptic receptors in the prefrontal cortex, modulating executive functions including the regulation of attention. Attention is affected ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoang, Karen, Watt, Hilary, Golemme, Mara, Perry, Richard J., Ritchie, Craig, Wilson, Danielle, Pickett, James, Fox, Chris, Howard, Robert, Malhotra, Paresh A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340683/ https://www.ncbi.nlm.nih.gov/pubmed/35915506 http://dx.doi.org/10.1186/s13063-022-06190-3

Ejemplares similares

Noradrenergic Modulation of Learned and Innate Behaviors in Dopamine Transporter Knockout Rats by Guanfacine
por: Volnova, Anna, et al.
Publicado: (2023)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging
por: Loreto, Flavia, et al.
Publicado: (2021)

New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease
por: David, Michael, et al.
Publicado: (2022)

A computational psychiatry approach identifies how alpha-2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque
por: Hassani, S. A., et al.
Publicado: (2017)

Aging well with Norad
por: Marques, Filipa Carvalhal, et al.
Publicado: (2019)

Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke
por: Dalmaijer, Edwin S, et al.
Publicado: (2018)

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

SAM68 is required for regulation of Pumilio by the NORAD long noncoding RNA
por: Tichon, Ailone, et al.
Publicado: (2018)

Effect of Enteral Guanfacine on Dexmedetomidine Use in the ICU
por: Fetters, Megan B., et al.
Publicado: (2022)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein
por: Gillis, Nancy K, et al.
Publicado: (2011)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium
por: Jiang, Shixie, et al.
Publicado: (2023)

Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis
por: David, Michael C B, et al.
Publicado: (2022)

Diagnostic implications of lncRNA NORAD in breast cancer
por: Zhang, Yaping, et al.
Publicado: (2023)

The Potential of NORAD–PUMILIO–RALGAPB Regulatory Axis as a Biomarker in Breast Cancer
por: Muller, Cristiane Sato Mara, et al.
Publicado: (2022)

Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale
por: Arnsten, Amy F.T., et al.
Publicado: (2012)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Stressing the potential of guanfacine as a treatment for cocaine use disorder
por: Lustberg, Daniel, et al.
Publicado: (2020)

Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions
por: Fukuyama, Kouji, et al.
Publicado: (2021)

Guanfacine as an effective drug for the treatment of tic disorder. Case report
por: Del Sol Calderon, P., et al.
Publicado: (2021)

PUMILIO hyperactivity drives premature aging of Norad-deficient mice
por: Kopp, Florian, et al.
Publicado: (2019)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2019)

Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration
por: Wagener, Nele, et al.
Publicado: (2022)

PUMILIO, but not RBMX, binding is required for regulation of genomic stability by noncoding RNA NORAD
por: Elguindy, Mahmoud M, et al.
Publicado: (2019)

Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression
por: Wang, Lili, et al.
Publicado: (2018)

LncRNA NORAD defects deteriorate the formation of age-related macular degeneration
por: Zhang, Jinfeng, et al.
Publicado: (2023)

Amendment to the Progress Report of the Director-General and Divisional Directors (CERN/319/Add.) (English version only)
Publicado: (1959)

Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol
por: Sandström, Katharina O., et al.
Publicado: (2022)

Noradrenergic symptom cluster in depression
por: Montgomery, Stuart, et al.
Publicado: (2011)

Noradrenergic dysfunction in Alzheimer's disease
por: Gannon, Mary, et al.
Publicado: (2015)

The Noradrenergic System in Parkinson’s Disease
por: Paredes-Rodriguez, Elena, et al.
Publicado: (2020)

Shining light on the noradrenergic system
por: Tanguay, Emmeraude, et al.
Publicado: (2023)

Effects of alpha 2-adrenoceptor agonists dexmedetomidine and guanfacine on morphine analgesia and tolerance in rats
por: Gursoy, Sinan, et al.
Publicado: (2011)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Successful use of guanfacine in a patient with chronic refractory cough: A case report
por: Kirschen, Gregory W., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a7kvbkcnu4c0tffs97dbmpip8i